Zacks Investment Research upgraded shares of KAMADA LTD (KMDA) from UNDERPERFORM to NEUTRAL on July 09, 2014, with a target price of $7.00.
Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on KAMADA LTD (KMDA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment